CellVec

Executive Summary

CellVec is a Singapore-based biotechnology company developing next-generation gene and cell therapy platforms. Founded in 2020, the company leverages proprietary vector engineering and cell-modulation technologies to create both off-the-shelf and autologous therapies targeting oncology and rare diseases. By integrating advanced manufacturing with AI-driven design, CellVec aims to accelerate discovery and scale production. The company is currently in the preclinical stage and operates with a lean team of 10-50 employees. While financial details and pipeline specifics are limited, its platform approach and focus on underexplored indications position it as a potential emerging player in the rapidly evolving cell and gene therapy space. The company operates in Singapore, a growing biotech hub with supportive regulatory and funding environments, which may facilitate future clinical development and partnerships.

Upcoming Catalysts (preview)

• Q3 2026Series A Financing Round60% success
• Q4 2026IND Filing for Lead Candidate35% success
• H2 2026Preclinical Data Presentation at Major Conference50% success